FXR shaped an immunosuppressive TME in NSCLC by inducing HVEM expression through transcriptional activation, intracellular Akt, Erk1/2 and STAT3 signaling pathways, and G1/S cycle progression. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.